Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis

Abstract Objective Type 2 diabetes mellitus (T2DM) increases the risk of sarcopenia, but evidence on the effects of glucagon-like peptide 1 receptor agonist (GLP-1 RA) in skeletal muscle is limited and inconsistent. The study aimed to evaluate the skeletal muscle mass of GLP-1 RA in patients with ty...

Full description

Bibliographic Details

Published in:	Diabetology & Metabolic Syndrome
Main Authors:	Yanying Wang, Boya Lan, Shuo Zhang, Yue Mu, Jia Mi, Jing Yu, Qun Zhan, Baoling Luo, Fuyang Lin, Jia Teng, Xiuge Wang, Guanchi Yan
Format:	Article
Language:	English
Published:	BMC 2025-08-01
Subjects:	Glucagon-like peptide 1 receptor agonist Type 2 diabetes Sarcopenia Skeletal muscle mass Meta-analysis
Online Access:	https://doi.org/10.1186/s13098-025-01877-4